Search Results
Found 1 results
510(k) Data Aggregation
The Olympus thyroid stimulating hormone (TSH) assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of TSH levels in human serum and plasma using the Olympus AU3000i™ Immunoassay System.
Measurements of TSH produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.
The Olympus TSH Calibrator is used for calibrating the quantitative Olympus TSH Assay on the Olympus AU3000i Immunoassay System.
The Olympus TSH Control is used for quality control of the Olympus TSH test system on the Olympus AU3000i Immunoassay System.
The Olympus AU3000i Immunoassay System is a chemiluminescent discrete photometric chemistry analyzer for the quantitative determination of analytes in human serum and plasma.
The Olympus TSH assay is a two-step paramagnetic particle enzyme immunoassay. It is based on the sandwich principle and used to quantitate TSH in serum/plasma.
The Olympus TSH assay reagent and sample are added to the assay cuvette in the following sequence:
- Samples are incubated first with a monoclonal anti-TSH antibody bound to paramagnetic particles.
- After a washing step, a second monoclonal anti-TSH antibody conjugated with alkaline phosphatase is added. The TSH reacts with the paramagnetic particles and the conjugated antibody to form a sandwich complex. Washing steps remove the unbound material.
- The chemiluminescent substrate is added to the assay cuvette and reacts with the bound alkaline phosphatase (ALP). Light generated by the reaction is measured by the luminometer. The light emission is proportional to the quantity of TSH in the sample.
- Results are calculated from a pre-defined calibration curve. The Olympus AU3000i system automatically calculates the TSH concentration of each sample in mIU/L or µIU/mL.
The provided 510(k) summary focuses on demonstrating substantial equivalence of the Olympus TSH Test System to predicate devices rather than establishing novel acceptance criteria and proving the device meets them with a dedicated study. Instead, the performance characteristics of the Olympus TSH Test System are compared directly to those of the predicate Roche Elecsys® TSH Test System.
Therefore, the response below will present the performance characteristics as a comparison to the predicate device, rather than explicit "acceptance criteria" and "reported device performance."
Here's the breakdown of the information requested, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
As this is a 510(k) submission demonstrating substantial equivalence, explicit "acceptance criteria" are not stated in the typical sense of a performance goal. Instead, the performance of the Olympus TSH Test System is compared directly to the predicate device, the Roche Elecsys® TSH Test System. The implicit acceptance criterion is that the performance of the new device is comparable to the predicate.
Performance Characteristic | Predicate Device Performance (Roche Elecsys® TSH) | Olympus TSH Test System Performance |
---|---|---|
Precision (Total CV%) | ||
Low Concentration | 8.7 | 2.9 |
Medium Concentration | 3.3 | 6.0 |
High Concentration | 3.6 | 3.7 |
Functional Sensitivity | 0.014 µIU/mL | 0.0013 µIU/mL |
Analytical Sensitivity | 0.005 µIU/mL | 0.0002 µIU/mL |
Measurable Range | 0.005 – 100.0 µIU/mL | 0.001 – 130 µIU/mL |
Method Comparison (Passing Bablok) | ||
Intercept | 0.01 | -0.0046 |
Slope | 1.01 | 0.935 |
R | 0.944 | 0.9931 |
Applicable Interfering Substances | ||
Bilirubin | ≤ 10% @ 41 mg/dL | ≤ 10% @ 40 mg/dL |
Hemolysis | ≤ 10% @ 1 g/dL | ≤ 5% @ 5 g/L |
Lipemia | ≤ 10% @ 1500 mg/dL | ≤ 3% @ 10 g/L |
Specificity (LH, FSH, hGH, hCG) | No significant interference for LH & FSH. hGH Not Detected. hCG Not Detected. | No significant interference for LH & FSH. hGH Not Tested. hCG Not Detected. |
2. Sample Size for the Test Set and Data Provenance
The document does not explicitly state the sample sizes used for the performance characteristic studies (e.g., precision, method comparison, interference). The data provenance (e.g., country of origin, retrospective/prospective) is also not specified.
3. Number of Experts and Qualifications for Ground Truth
For in vitro diagnostic (IVD) devices like the Olympus TSH Test System, "ground truth" is typically established through reference methods, certified calibrators, or established analytical techniques, rather than expert human interpretation (like radiologists). The document indicates traceability to "WHO" (World Health Organization) for both the predicate and proposed device, implying the use of international reference standards. No human experts are mentioned for establishing ground truth.
4. Adjudication Method for the Test Set
Not applicable for an IVD device where ground truth is typically assessed through quantitative analytical methods and reference standards, not human adjudication of subjective interpretations.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
Not applicable. This is an in vitro diagnostic device for quantitative determination of TSH levels, not an imaging or diagnostic aid for human readers.
6. Standalone Performance Study
Yes, the performance characteristics listed in the table above (Precision, Functional Sensitivity, Analytical Sensitivity, Measurable Range, Method Comparison, Interference, Specificity) represent the standalone (algorithm/device only) performance of the Olympus TSH Test System. These are intrinsic analytical performance metrics of the device itself.
7. Type of Ground Truth Used
The ground truth for this type of IVD device is based on reference materials, certified calibrators, and/or comparison to a well-established and accepted reference method. The document states "Traceability: WHO" for both the Olympus TSH Test System (WHO 3rd IS 81/565) and the predicate (WHO 2nd IRP 80/558), indicating that the results are standardized against internationally recognized standards for TSH measurement.
8. Sample Size for the Training Set
The document does not specify a separate "training set" sample size. For IVD devices, method development and optimization studies are conducted, but usually, a distinct "training set" and "test set" in the context of machine learning (where this terminology is common) are not explicitly detailed in 510(k) summaries for traditional immunoassay systems. The performance characteristics described are typically derived from verification and validation studies.
9. How Ground Truth for the Training Set Was Established
Not explicitly detailed as a "training set" in the machine learning sense. However, for the development and calibration of such an assay, ground truth would be established through a combination of:
- Using calibrators with known TSH concentrations (e.g., Olympus TSH Calibrator, referenced to WHO standards).
- Testing against reference samples or patient samples analyzed by established, validated reference methods, often traceable to international standards.
- The "Olympus TSH Calibrator is used for calibrating the quantitative Olympus TSH Assay," and its matrix is "Bovine serum human pituitary TSH," implying that the calibrators themselves embody the "ground truth" for the device's measurement scale.
Ask a specific question about this device
Page 1 of 1